LLY: Eli Lilly And Co Stock

by  •  • Comments Off on LLY: Eli Lilly And Co Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 309,576.19
Enterprise Value ($M) 324,619.99
Book Value ($M) 10,165.90
Book Value / Share 11.27
Price / Book 30.45
NCAV ($M) -20,679.90
NCAV / Share -22.93
Price / NCAV -14.97

Profitability (mra)
Return on Invested Capital (ROIC) 0.23
Return on Assets (ROA) 0.13
Return on Equity (ROE) 0.68

Liquidity (mrq)
Quick Ratio 0.80
Current Ratio 1.05

Balance Sheet (mrq) ($M)
Current Assets 18,034.50
Assets 49,489.80
Liabilities 38,714.40
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 28,541.40
Operating Income 8,280.40
Net Income 6,244.80
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 7,084.40
Cash from Investing -3,261.60
Cash from Financing -5,406.70

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-10 13G/A Pnc Financial Services Group, Inc. 5.25 -0.11
02-09 13G/A Vanguard Group Inc 7.73 6.02
02-01 13G/A BlackRock Inc. 6.90 2.49
01-25 13G/A Lilly Endowment Inc 10.83 -4.20

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2023-02-22 10-K United States Securities and Exchange Commission Washington, D.C. 20549 Form 10-K Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2022 Commission file number 001-06351 ELI LI
2022-11-01 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2022 COMMISSION FILE NUMBER 001-635
2022-08-04 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2022 COMMISSION FILE NUMBER 001-6351 ELI
2022-04-29 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2022 COMMISSION FILE NUMBER 001-6351 EL

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2023-03-31 339,604 1,979,155 17.16
2023-03-30 326,075 1,678,617 19.43
2023-03-29 421,885 2,107,123 20.02
2023-03-28 326,922 1,856,917 17.61
2023-03-27 548,442 2,598,332 21.11

(click for more detail)

Similar Companies
JATT.U – JATT Acquisition Corp Units, each consisting of one Class A ordinary share, and one-half of one rede JNJ – Johnson & Johnson
LCI – Lannett Company, Inc. MRK – Merck & Co., Inc.
MYOV – Myovant Sciences Ltd.


Financial data and stock pages provided by
Fintel.io